Cytosorbents (CTSO) SEC Filings: History & Chart

Cytosorbents Corporation(CTSO)

Medical - Devices · Princeton, NJ

$4.02+0.05 (+1.39%)

Delayed quote: Oct 6, 2026, 3:53 PM EDT

About Cytosorbents Corporation

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's leading product, CytoSorb, is an extracorporeal filter designed to remove cytokines from the blood. It serves as a complementary treatment in various critical care scenarios, including sepsis, managing complications during and after heart bypass surgery, and improving the viability of donor organs for transplantation. Beyond CytoSorb, Cytosorbents offers a portfolio of specialized devices. These include VetResQ, used to assist in treating critical conditions like sepsis and pancreatitis in animals; CytoSorb-XL, another device targeting sepsis and other severe illnesses; HemoDefend, a platform for purifying blood supplies by removing contaminants that cause transfusion reactions and diseases, as well as anti-A and anti-B antibodies from blood products; K+ontrol, designed for patients with severe, life-threatening hyperkalemia; and ContrastSorb, which extracts intravenous contrast agents following imaging procedures (like CT scans, angiograms, or interventional radiology) to mitigate the risk of contrast-induced kidney damage. The company is also actively developing several new solutions: BetaSorb, aimed at preventing and treating complications from metabolic toxin buildup in chronic kidney disease patients; DrugSorb, which focuses on eliminating harmful chemicals from the bloodstream; and DrugSorb-ATR, an innovative system for removing antithrombotic agents. Originally established as MedaSorb Technologies Corporation in 1997, the company adopted its current name, Cytosorbents Corporation, in May 2010. Its corporate headquarters are situated in Princeton, New Jersey.

Princeton, NJ

129 employees

www.cytosorbents.com

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Phillip Chan

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 23, 2026	Sep 23, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 16, 2026	Sep 16, 2026	View filing
4	Sep 9, 2026	Sep 9, 2026	View filing
8-K	Sep 8, 2026	Sep 8, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 7, 2026	Aug 7, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Jul 6, 2026	Jul 6, 2026	View filing
ARS	Jun 25, 2026	Jun 25, 2026	View filing
DEFA14A	Jun 25, 2026	Jun 25, 2026	View filing
DEF 14A	Jun 25, 2026	Jun 25, 2026	View filing
8-K	Jun 25, 2026	Jun 25, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 15, 2026	Jun 15, 2026	View filing
PRE 14A	Jun 11, 2026	Jun 11, 2026	View filing
10-Q	May 13, 2026	May 13, 2026	View filing
8-K	May 13, 2026	May 13, 2026	View filing
10-K/A	Apr 15, 2026	Apr 15, 2026	View filing
8-K	Apr 2, 2026	Apr 2, 2026	View filing
10-K	Mar 30, 2026	Mar 30, 2026	View filing
8-K	Mar 25, 2026	Mar 25, 2026	View filing
SC 13G/A	Feb 13, 2026	Feb 13, 2026	View filing
4	Nov 20, 2025	Nov 20, 2025	View filing
8-K	Nov 13, 2025	Nov 13, 2025	View filing
10-Q	Nov 13, 2025	Nov 13, 2025	View filing
8-K	Oct 3, 2025	Oct 3, 2025	View filing
8-K	Sep 16, 2025	Sep 16, 2025	View filing

SEC Filings

Recent Filings